AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03315338
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules, orally administered
Trial: NCT03315338
Drug: CORT118335, dose to be determined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CORT118335 is supplied as suspension for oral dosing
Trial: NCT04046510
Drug: Ocytocin
RxNorm normalized name: Neurosecretory granule protease cleaving pro-ocytocin/neurophysin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of lower doses of Ocytocin in bolus and continuous infusion
Trial: NCT03781362
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine will be administered 1000 mg/m2 orally twice a day for 2 weeks followed by a 7-day rest period
Trial: NCT01547143
Drug: IST and/or alloHCT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1) Patients will be categorized by their initial serum ferritin level.~1. Mild ( ferritin\<3,000 μg/L): close observation~2. Moderate (ferritin: 3,000-10,000 μg/L):~   1. Initiation : cyclosporine 3mg/kg p.o.bid + dexamethasone 10mg/m2/d po. or i.v. (D1-3)~  2. continuation: cyclosporine 3mg/kg p.o. bid (D4-56) + dexamethasone 10mg/m2/d (D4-14), then tapering.~3. Severe (ferritin\>10,000 μg/L):~   1. initiation : etoposide 100mg/m2/d i.v. + cyclosporine 2mg/kg i.v. q 12hours + dexamethasone 20mg/m2/d i.v. (D1-3)~  2. continuation : etoposide 100mg/m2/day weekly (D15-49) + cyclosporine 2mg/kg i.v. q 12 hours? ? po. (D4-56) + dexamethasone 10mg/m2/d (D4-14), 5mg/m2/d (D15-28), 2.5mg/m2/d (D29-42), 1.25mg/m2/d (D43-56), then tapering off.~      2) AlloHCT for refractory or reactivated cases.
Trial: NCT02457806
Drug: Placebo spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous solution to deliver 0.1 mL per unit
Trial: NCT00703391
Drug: AZD9668
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30mg oral tablets twice daily (bid) for 14 days
Trial: NCT00703391
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo to 30mg oral tablet twice daily (bid) for 14 days
Trial: NCT00738959
Drug: AZD0328
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution A single dose Day 1 followed by once daily doses on Day 3-7
Trial: NCT03905642
Drug: Arikayce™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amikacin (aminoglycoside) in a liposomal formulation.
Trial: NCT03221855
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules 10mg orally each 8 hours for 7 days.
Trial: NCT00779389
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 14-21 days.
Trial: NCT01680861
Drug: Enteric Coated Mycophenolate Sodium (EC-MPS)
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EC-MPS 720 mg PO BID - beginning on 1st postoperative day.
Trial: NCT01680861
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids will be given as per our center protocol, i.e., a bolus of 500 mg of Methylprednisolone intravenously at surgery and daily x2, followed by 1.0 mg/kg, then 0.5 mg/kg orally until weaned off completely by 7-10 days postoperatively - the plan is for corticosteroids to be discontinued by 7-10 days postoperatively in both groups.
Trial: NCT01920932
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV.
Trial: NCT01920932
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV.
Trial: NCT00827216
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For all patients, a standardised volume of 10 ml of the study drug (will be diluted in 90 ml NaCl 0.9% (total volume, 100 ml). Both, the study drug and the 90 ml NaCl bag will be prepared by the pharmacy. Using sterile syringes, the investigator will withdraw from this solution as many millilitres as necessary to obtain a volume that corresponds to 1 ml per kg bodyweight of the patient (i.e. for a 67 kg patient, 33 ml would be with withdrawn). Thus, the maximum volume that can be administered to a patient will be 100 ml (i.e. for a patient weighing ≥100 kg). Twenty minutes prior to the scheduled induction of anaesthesia, patients will receive their study drug solution as an intravenous infusion during 5 min.
Trial: NCT00827216
Drug: Erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For all patients, a standardised volume of 10 ml of the study drug (will be diluted in 90 ml NaCl 0.9% (total volume, 100 ml). Both, the study drug and the 90 ml NaCl bag will be prepared by the pharmacy. Using sterile syringes, the investigator will withdraw from this solution as many millilitres as necessary to obtain a volume that corresponds to 1 ml per kg bodyweight of the patient (i.e. for a 67 kg patient, 33 ml would be with withdrawn). Thus, the maximum volume that can be administered to a patient will be 100 ml (i.e. for a patient weighing ≥100 kg). Twenty minutes prior to the scheduled induction of anaesthesia, patients will receive their study drug solution as an intravenous infusion during 5 min. The regimen corresponds to 3 mg/kg of erythromycin.
Trial: NCT01521390
Drug: GSK573719 62.5 mcg (one strip)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK573719 62.5 mcg delivered by 1 strip configuration of novel dry powder inhaler
Trial: NCT01521390
Drug: GSK573719 62.5 mcg(two strips)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK573719 62.5 mcg delivered by 2 strip configuration of novel dry powder inhaler
Trial: NCT01521390
Drug: GSK573719 125 mcg (one strip)
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK573719 125 mcg delivered by 1 strip configuration of novel dry powder inhaler
Trial: NCT01521390
Drug: GSK573719 125 mcg(two strips)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK573719 125 mcg delivered by 2 strip configuration of novel dry powder inhaler
Trial: NCT01521390
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, no active ingredient
Trial: NCT04221256
Drug: Administration of Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be administered a placebo prior to paired associative stimulation
Trial: NCT03678688
Drug: 3 mg OPC-167832
RxNorm normalized name: naphazoline hydrochloride 0.27 MG/ML / pheniramine maleate 3.15 MG/ML [Opcon-A]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily oral dose of 3 mg OPC-167832 from Day 1 through Day 14.
Trial: NCT02959411
Drug: Standard of care diuretic therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual standard of care diuretic therapy for patients hospitalized with acute decompensated heart failure
Trial: NCT00329537
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-subcutaneous injection
Trial: NCT02192632
Drug: Epiduo- once daily, simple instruction for application
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04711291
Drug: Convert to Envarsus XR once daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convert from tacrolimus immediate release to tacrolimus extended release (Envarsus XR) prescribed dose every 24 hours
Trial: NCT00837291
Drug: CF101
RxNorm normalized name: CF101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CF101 tablets 1 mg BID
Trial: NCT00837291
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets BID
Trial: NCT03540524
Drug: GLPG2451 dose regimen A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG2451 oral suspension, daily.
Trial: NCT03540524
Drug: GLPG2451 dose regimen B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG2451 oral suspension, daily.
Trial: NCT03540524
Drug: GLPG2222
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG2222 tablet for oral use, daily.
Trial: NCT03540524
Drug: GLPG2737
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG2737 capsules for oral use, daily.
Trial: NCT00856687
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, two doses 12 hours apart
Trial: NCT03960645
Drug: B/F/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50/200/25 mg FDC tablet administered orally once daily without regard to food.
Trial: NCT03185793
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily for 5 weeks
Trial: NCT03185793
Drug: SHR4640
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1mg SHR4640 once daily for a week, 2.5mg, 5mg or 10mg SHR4640 once daily for 4 weeks
Trial: NCT01332552
Drug: GSK2485852 70 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose
Trial: NCT01332552
Drug: GSK2485852 420 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose
Trial: NCT01332552
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose
Trial: NCT01332552
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeat dose, once daily for 3 days
Trial: NCT01332552
Drug: GSK2485852 420 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeat dose, twice daily for 3 days
Trial: NCT01332552
Drug: GSK2485852 420 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeat dose, TIDfor 3 days
Trial: NCT01332552
Drug: GSK2485852 630 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeat dose, twice daily for 3 days
Trial: NCT03263117
Drug: Sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The protocol does not specify a particular combination of drugs that must be used for sedation.~The most common drugs utilized for sedation and wide dosing ranges are included in the protocol (i.e., sedation will be provided under the supervision of an anesthesiologist and may use a combination of fentanyl, midazolam, dexmedetomidine infusion (with or without loading dose), and/or low-dose propofol by intermittent bolus or infusion); however, the choice of specific drugs and dosages for achieving conscious sedation or general anesthesia will not be specified by the protocol but will be up to the anesthesiologist.
Trial: NCT03263117
Drug: General Anesthesia (GA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The protocol doesn't specify drugs that must be used for GA, the choice of drugs and dosages for achieving general anesthesia will not be specified by the protocol but will be up to the anesthesiologist.~The most common drugs utilized for GA and wide dosing ranges included in the protocol are (GA will be provided under the supervision of an anesthesiologist and induction of anesthesia may be achieved with propofol and/or etomidate; muscle paralysis may be achieved with succinylcholine or non-depolarizing paralytic (rocuronium or vecuronium); and adjuvant lidocaine and fentanyl; if intravenous maintenance of anesthesia is used, it may be achieved by propofol infusion at 50 to 150 mcg/kg/min with redosing of non-depolarizing paralytic and fentanyl as needed; if inhalational maintenance of anesthesia is used it will be achieved with sevoflurane 1% to 2% or desflurane 3% to 6% end-tidal concentration with redosing of non-depolarizing paralytic and fentanyl as needed)
Trial: NCT01450007
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ml normal saline (intravenous)
Trial: NCT00680602
Drug: SSRI (fluoxetine, sertraline, paroxetine, citalopram)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (80mg/day or maximum tolerated dosage) Sertraline (200mg/day or maximum tolerated dosage) Paroxetine (60 mg/day or maximum tolerated dosage) Citalopram (60 mg/day or maximum tolerated dosage)
Trial: NCT01450007
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 ml normal saline (perineural)
Trial: NCT00712413
Drug: OBMT
RxNorm normalized name: Oxbutynin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg twice daily, in combination with bismuth subcitrate potassium (40 mg), metronidazole 125 mg and tetracycline 125 mg HCl. All patients must take 6 capsules of Pylera, in addition to 1 omeprazole twice daily
Trial: NCT00703352
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eplerenone (coated tablet) 50mg daily during 12 months.
Trial: NCT04313699
Drug: Antiretroviral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The cohort will recruit HIV infected participants who are on antiretroviral treatment
Trial: NCT03936166
Drug: Placebo Oral Capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01596686
Drug: one of two possible colon preparation regimens
RxNorm normalized name: Sus scrofa colon preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients are randomized to receive one of the two different preparation regimens for colonoscopy usually employed in our unit, polyethylene glycol or sodium picosulphate and magnesium citrate
Trial: NCT01337752
Drug: BHQ880
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01337752
Drug: BHQ880 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT00001615
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02431442
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02983188
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets, 0.3g every time, two times daily
Trial: NCT02983188
Drug: Antipsychotic Agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic agents prescribed at the discretion of the patients' psychiatrists with respect to patients' conditions. Concomitant use of other psychotropic drugs, including antidepressants, anxiolytics, and mood stabilizers for mood disorders, benzodiazepines and non-benzodiazepines for insomnia, and anticholinergics for extrapyramidal symptoms, was allowed as usual. For those who were under anti-hyperlipidemic, antihypertensive and anti-diabetic treatment, they were allowed to continue their current medications throughout the study.
Trial: NCT02709005
Drug: 5% Monolaurin Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monolaurin Vaginal Gel is a clear and colorless, non-sterile glycol-based gel for vaginal administration , and commonly referred to as glycerol monolaurate (GML). Each subject will receive intravaginal gel twice daily for three successive days for a total of 6 doses. There will be 3 clinic visits over 30 days.
Trial: NCT01921712
Drug: PUR0200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized single doses of 3 selected doses of PUR0200, compared to a placebo and active comparator
Trial: NCT01921712
Drug: PUR0200 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized, single dose of inhaled placebo matched to PUR0200
Trial: NCT03616574
Drug: CA102N
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CA102N is a covalently bound conjugate of the biological polymer sodium hyaluronate (NaHA) and nimesulide (Nim).
Trial: NCT03863405
Drug: Conventional DMARDs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: methotrexate, leflunomide, hydroxychloroquine or sulfasalazine
Trial: NCT03863405
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet
Trial: NCT04336709
Drug: Calcipex II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water based intracanal medicament
Trial: NCT04336709
Drug: Metapex
RxNorm normalized name: metaproterenol sulfate Oral Tablet [Metaprel]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oil based intracanal medicament
Trial: NCT03068312
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to IVA tablet.
Trial: NCT01755559
Drug: Artemether-lumefantrine
RxNorm normalized name: artemether-lumefantrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antimalarial ACT
Trial: NCT01349998
Drug: Product 33525
RxNorm normalized name: Pyelocalyceal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dosing for 2 weeks each recurrence for patients with tinea pedis and Daily dosing for 1 week each recurrence for patients with tinea cruris and tinea corporis
Trial: NCT02404844
Drug: BKM120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily oral
Trial: NCT01343680
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5ml 10 units/ml IV heparin 3 times per week
Trial: NCT01343680
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10ml normal saline IV weekly
Trial: NCT00880854
Drug: BCG and CP-675,206
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose level -1: BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 CP-675,206 3 mg/kg I.V. week 3, week 15~Dose level 1: BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 CP-675,206 6 mg/kg I.V. week 3, week 15~Dose level 2: BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 CP-675,206 10 mg/kg IV week 3, week 15~Dose level 3: BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 CP-675,206 15 mg/kg IV week 3, week 15
Trial: NCT02792543
Drug: parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition (the gold standard treatment) consists of electrolyte supplementation, hydration, and nutrition through a central venous catheter.
Trial: NCT03418233
Drug: CardioCell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to the active treatment group will receive transcoronary or trans-bypass graft administration of 30 000 000 cells (suspended in 20 ml of 0.9% NaCl and 5% albumin).~Injection will be performed using a dedicated cell delivery catheter. The cell delivery catheter is a typical coronary balloon catheter that is CE marked (1.2x10 mm balloon, RX system) modified to include cell delivery perforations in the balloon section of the catheter. The cell delivery catheter has been demonstrated not to affect cell viability or other cell properties.
Trial: NCT03418233
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to the placebo group will receive Placebos consist 0.9% NaCl and 5% albumin injections (in the same volumes as CardioCell) via the coronary arter(ies)/bypass grafts. The CardioCell and placebo are distributed encoded, in an indistinguishable form.
Trial: NCT00877487
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule (identical to drug capsules) per day for 4 weeks during the double blind period.
Trial: NCT01167933
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 80 mg tablets Dr. Reddy's Laboratories Ltd
Trial: NCT02841280
Drug: Chlorthalidone
RxNorm normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a forced-titration study and the study drug will be increased if goal BP is not achieved (dosage of chlorthalidone not to exceed 50 mg)
Trial: NCT02841280
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a forced-titration study and placebo will be increased if goal BP is not achieved.
Trial: NCT02246179
Drug: AHES
RxNorm normalized name: STOMAHESIVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application at test region 1 and 3 under occlusion for 10 minutes
Trial: NCT04934579
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3.5g/m2 intravenous infusion for 4 hours in d1, every 21 days for 1 cycle, 6 cycles will be prescribed.
Trial: NCT01127282
Drug: Placebo (digestive tablet)
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (digestive tablet) 1T po for 5 days in addition to anti-viral agent and antipyretics
Trial: NCT03963232
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT01354145
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib 200 mg/day, 24 months treatment period
Trial: NCT02832128
Drug: AUT00063
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 capsules of 200 mg AUT00063, to take orally with food for 4 weeks
Trial: NCT02832128
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 capsules of placebo, to take orally with food for 4 weeks
Trial: NCT00734578
Drug: SPD503-AM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPD503 (Guanfacine Extended Release)-AM Optimized 1-4mg
Trial: NCT00734578
Drug: SPD503-PM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPD503 (Guanfacine Extended Release)-PM Optimized 1-4mg
Trial: NCT00734578
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to Guanfacine Hydrochloride Extended Release
Trial: NCT04094207
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets PLUS Risperidone 2 mg tablet up to 6 mg/day
Trial: NCT02586038
Drug: MLN9708
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02586038
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00207584
Drug: Doxycycline treatment
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no